REGN · Regeneron Pharmaceuticals, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Dupixent® global net sales (recorded by Sanofi) | 6B | Second quarter 2026 | — |
| EYLEA HD® U.S. net sales | $596M | Q2 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $1.42B | Six Months Ended June 30, 2026 | — |
| Libtayo® global net sales | $489M | Q2 2026 | +29.9% |
|
|
|||
| Non-GAAP gross margin on net product sales non-GAAP | 86% | Six Months Ended June 30, 2026 | — |
| Total EYLEA HD and EYLEA - U.S. | $1.01B | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
REGN
this stock
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +8.9% | +20.8% | 20.8 | 3.3% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +24.0% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
MRNA
Moderna, Inc.
|
$69.62B | +491.3% | +4.3% | — | 12.5% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| REGN | +5.4% | +29.1% | +9.1% | +10.3% | +8.9% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +5.8% | +26.2% | -2.5% | +7.3% | -3.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.